193 related articles for article (PubMed ID: 37934630)
21. Brain tissue gadolinium retention in pediatric patients after contrast-enhanced magnetic resonance exams: pathological confirmation.
Stanescu AL; Shaw DW; Murata N; Murata K; Rutledge JC; Maloney E; Maravilla KR
Pediatr Radiol; 2020 Mar; 50(3):388-396. PubMed ID: 31989188
[TBL] [Abstract][Full Text] [Related]
22. Gadolinium Presence in the Brain After Administration of the Liver-Specific Gadolinium-Based Contrast Agent Gadoxetate: A Systematic Comparison to Multipurpose Agents in Rats.
Jost G; Frenzel T; Boyken J; Schoeckel L; Pietsch H
Invest Radiol; 2019 Aug; 54(8):468-474. PubMed ID: 30932931
[TBL] [Abstract][Full Text] [Related]
23. Increased signal intensities in the dentate nucleus and globus pallidus on unenhanced T1-weighted images: evidence in children undergoing multiple gadolinium MRI exams.
Hu HH; Pokorney A; Towbin RB; Miller JH
Pediatr Radiol; 2016 Oct; 46(11):1590-8. PubMed ID: 27282825
[TBL] [Abstract][Full Text] [Related]
24. Risks and Benefits of Gadolinium-Based Contrast-Enhanced MRI.
Costelloe CM; Amini B; Madewell JE
Semin Ultrasound CT MR; 2020 Apr; 41(2):170-182. PubMed ID: 32446430
[TBL] [Abstract][Full Text] [Related]
25. Gadolinium-based contrast exposure, nephrogenic systemic fibrosis, and gadolinium detection in tissue.
Wiginton CD; Kelly B; Oto A; Jesse M; Aristimuno P; Ernst R; Chaljub G
AJR Am J Roentgenol; 2008 Apr; 190(4):1060-8. PubMed ID: 18356456
[TBL] [Abstract][Full Text] [Related]
26. Gadolinium-Based Contrast Agents in Kidney Disease: Comprehensive Review and Clinical Practice Guideline Issued by the Canadian Association of Radiologists.
Schieda N; Blaichman JI; Costa AF; Glikstein R; Hurrell C; James M; Jabehdar Maralani P; Shabana W; Tang A; Tsampalieros A; van der Pol C; Hiremath S
Can Assoc Radiol J; 2018 May; 69(2):136-150. PubMed ID: 29706252
[TBL] [Abstract][Full Text] [Related]
27. Gadolinium deposition and the potential for toxicological sequelae - A literature review of issues surrounding gadolinium-based contrast agents.
Layne KA; Dargan PI; Archer JRH; Wood DM
Br J Clin Pharmacol; 2018 Nov; 84(11):2522-2534. PubMed ID: 30032482
[TBL] [Abstract][Full Text] [Related]
28. High Signal Intensity in Dentate Nucleus on Unenhanced T1-weighted MR Images: Association with Linear versus Macrocyclic Gadolinium Chelate Administration.
Kanda T; Osawa M; Oba H; Toyoda K; Kotoku J; Haruyama T; Takeshita K; Furui S
Radiology; 2015 Jun; 275(3):803-9. PubMed ID: 25633504
[TBL] [Abstract][Full Text] [Related]
29. A new manganese-based oral contrast agent (CMC-001) for liver MRI: pharmacological and pharmaceutical aspects.
Jørgensen JT; Rief M; Brismar TB; Wagner M; Albiin N
Acta Radiol; 2012 Sep; 53(7):707-13. PubMed ID: 22821959
[TBL] [Abstract][Full Text] [Related]
30. Use and Safety of Gadolinium Based Contrast Agents in Pediatric MR Imaging.
Holowka S; Shroff M; Chavhan GB
Indian J Pediatr; 2019 Oct; 86(10):961-966. PubMed ID: 30796704
[TBL] [Abstract][Full Text] [Related]
31. Gadolinium retention: should pediatric radiologists be concerned, and how to frame conversations with families.
Noda SM; Oztek MA; Stanescu AL; Maloney E; Shaw DWW; Iyer RS
Pediatr Radiol; 2022 Feb; 52(2):345-353. PubMed ID: 33978802
[TBL] [Abstract][Full Text] [Related]
32. Safety and Gadolinium Distribution of the New High-Relaxivity Gadolinium Chelate Gadopiclenol in a Rat Model of Severe Renal Failure.
Fretellier N; Rasschaert M; Bocanegra J; Robert P; Factor C; Seron A; Idée JM; Corot C
Invest Radiol; 2021 Dec; 56(12):826-836. PubMed ID: 34091462
[TBL] [Abstract][Full Text] [Related]
33. Preliminary experience with intravenous gadoxetate disodium as a craniospinal MR contrast agent.
McKinney AM; Gawande R; Pezeshk P; Truwit CL; Rykken JB
Eur J Radiol; 2015 Dec; 84(12):2539-47. PubMed ID: 26456308
[TBL] [Abstract][Full Text] [Related]
34. Gadobutrol: a review of its use for contrast-enhanced magnetic resonance imaging in adults and children.
Scott LJ
Clin Drug Investig; 2013 Apr; 33(4):303-14. PubMed ID: 23435930
[TBL] [Abstract][Full Text] [Related]
35. Alternatives to GBCA: Are We There Yet?
Wesolowski JR; Kaiser A
Top Magn Reson Imaging; 2016 Aug; 25(4):171-5. PubMed ID: 27367312
[TBL] [Abstract][Full Text] [Related]
36. Gadolinium-based contrast agent toxicity: a review of known and proposed mechanisms.
Rogosnitzky M; Branch S
Biometals; 2016 Jun; 29(3):365-76. PubMed ID: 27053146
[TBL] [Abstract][Full Text] [Related]
37. Gadolinium Deposition in the Brain: Current Updates.
Choi JW; Moon WJ
Korean J Radiol; 2019 Jan; 20(1):134-147. PubMed ID: 30627029
[TBL] [Abstract][Full Text] [Related]
38. Manganese-Based Contrast Agents for Magnetic Resonance Imaging of Liver Tumors: Structure-Activity Relationships and Lead Candidate Evaluation.
Wang J; Wang H; Ramsay IA; Erstad DJ; Fuchs BC; Tanabe KK; Caravan P; Gale EM
J Med Chem; 2018 Oct; 61(19):8811-8824. PubMed ID: 30204438
[TBL] [Abstract][Full Text] [Related]
39. Patterns of use, effectiveness and safety of gadolinium contrast agents: a European prospective cross-sectional multicentre observational study.
Jakobsen JÅ; Quattrocchi CC; Müller FHH; Outteryck O; Alcázar A; Reith W; Fraga P; Panebianco V; Sampedro A; Pietura R
BMC Med Imaging; 2021 Apr; 21(1):74. PubMed ID: 33879075
[TBL] [Abstract][Full Text] [Related]
40. Revisiting the Pharmacokinetic Profiles of Gadolinium-Based Contrast Agents: Differences in Long-Term Biodistribution and Excretion.
Lancelot E
Invest Radiol; 2016 Nov; 51(11):691-700. PubMed ID: 27175546
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
